Sign In
Buy CLVS
$0.151
+0 (+0%)
At Close: Apr 19, 2023
Why Merrimack Pharmaceuticals Shares Jumped Around 213%; Here Are 114 Biggest Movers From Yesterday
10:12am, Thursday, 10'th Nov 2022 Benzinga
Gainers
Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) shares climbed 212.8% to close at $12.51 on Wednesday after partner Ipsen reported Onivyde met its primary and key secondary endpoint. Merrimac
Nasdaq Drops 200 Points; Meta Platforms Shares Jump
07:24pm, Wednesday, 09'th Nov 2022 Benzinga
U.S. stocks traded lower toward the end of trading , with the Nasdaq Composite dropping 200 points on Wednesday.
The Dow traded down 1.44% to 32,684.65 while the NASDAQ fell 1.89% to 10,416.00. The S&
Why RumbleON Shares Are Trading Higher By Around 28%? Here Are 84 Stocks Moving In Wednesday's Mid-Day Session
05:33pm, Wednesday, 09'th Nov 2022 Benzinga
Gainers
Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) shares jumped 219% to $12.80 after partner Ipsen reported Onivyde met its primary and key secondary endpoint. Merrimack is eligible for up to $
Crude Oil Down Over 2%; Outset Medical Shares Spike Higher
05:19pm, Wednesday, 09'th Nov 2022 Benzinga
U.S. stocks traded lower midway through trading as investors focused on the outcome of the midterm elections.
The Dow traded down 0.64% to 32,950.16 while the NASDAQ fell 0.76% to 10,535.77. The S&P 5
Clovis Oncology (CLVS) Reports Q3 Loss, Lags Revenue Estimates
02:55pm, Wednesday, 09'th Nov 2022 Zacks Investment Research
Clovis (CLVS) delivered earnings and revenue surprises of 7.14% and 11.87%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Why Is Clovis Oncology (CLVS) Stock Down 72% Today?
01:18pm, Wednesday, 09'th Nov 2022
Clovis Oncology (NASDAQ: CLVS ) stock is crashing on Wednesday as investors react to news of the company running out of cash! According to a recent filing from Clovis Oncology, there's a strong chance
Clovis Oncology stock slides 75% after biotech warns it will run out of cash by January of 2023
12:37pm, Wednesday, 09'th Nov 2022
Clovis Oncology Inc. shares CLVS, -73.37% plunged 75% Wednesday, after the Colorado-based biotech said it will not have sufficient liquidity to maintain operations beyond January of 2023. The company
Clovis Oncology: Looking Like An Acquisition Target After Recent Company Updates
02:18am, Saturday, 29'th Oct 2022
Clovis Oncology continues to report positive clinical data from Rubraca and FAP-2286. I believe these updates make Clovis a prime acquisition target. I review some of the company's recent updates.
BOULDER, Colo.
Guardant Health (GH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
02:03pm, Thursday, 27'th Oct 2022 Zacks Investment Research
Guardant Health (GH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Clovis Oncology (CLVS) Report Negative Q3 Earnings? What You Should Know
02:02pm, Wednesday, 26'th Oct 2022 Zacks Investment Research
Clovis (CLVS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Clovis Oncology (CLVS) Stock Up Today?
11:26am, Monday, 03'rd Oct 2022
In a still-fresh press release, Clovis Oncology (NASDAQ: CLVS ) just announced that its Phase 3 trial for Rubraca, a prostate cancer treatment, achieved its primary endpoint. Moreover, Clovis plans to
What Is Going on With Clovis Oncology (CLVS) Stock Today?
12:16pm, Wednesday, 21'st Sep 2022
Source: rafapress / Shutterstock.com Clovis Oncology (NASDAQ: CLVS ) stock is getting a boost on Wednesday as investors react to news of it reaching a two-year clinical supply agreement. That agreemen
Why SOBR Safe Shares Surged Around 233%; Here Are 68 Biggest Movers From Yesterday
07:04am, Wednesday, 21'st Sep 2022 Benzinga
Gainers
SOBR Safe, Inc. (NASDAQ: SOBR) shares surged 232.8% to settle at $3.03 on Tuesday following a report suggesting The National Transportation Safety Board is recommending that NHTSA require pas
Why Virios Therapeutics Is Trading Lower By 75%, Here Are 44 Stocks Moving In Tuesday's Mid-Day Session
04:41pm, Tuesday, 20'th Sep 2022 Benzinga
Gainers
Crown ElectroKinetics Corp. (NASDAQ: CRKN) shares jumped 51% to $0.4957. Crown ElectroKinetics, last month, posted a Q4 net loss of $4.5 million.
Virax Biolabs Group Limited (NASDAQ: VRAX) g
